Is Less Really More? When it comes to GLP-1 medications like Ozempic and Wegovy, that’s the question more providers and patients are starting to ask. Originally approved for type 2 diabetes and later for obesity treatment, GLP-1 and other incretin-based therapies have rapidly gained traction in both clinical and consumer spaces. If you’re newer to prescribing or supporting GLP-1 therapy, I’ve put together a four-part series covering key considerations, including initiation, weight management, cost, and side effect mitigation. Now, a new conversation is emerging: GLP-1 microdosing. What does microdosing mean in this context? Does it have clinical merit? And who…